Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Opna Bio’s OPN-2853 secures FDA’s orphan drug status for myelofibrosis
Myelofibrosis is a rare blood cancer causing bone marrow scarring, severe fatigue, anaemia, and enlarged spleen. Credit: Nemes Laszlo / Shutterstock.com.
Myelofibrosis is a rare blood cancer causing bone marrow scarring, severe fatigue, anaemia, and enlarged spleen. Credit: Nemes Laszlo / Shutterstock.com.